SI2310382T1 - Amidofenoksiindazoli uporabni kot inhibitorji c-met - Google Patents

Amidofenoksiindazoli uporabni kot inhibitorji c-met

Info

Publication number
SI2310382T1
SI2310382T1 SI200930193T SI200930193T SI2310382T1 SI 2310382 T1 SI2310382 T1 SI 2310382T1 SI 200930193 T SI200930193 T SI 200930193T SI 200930193 T SI200930193 T SI 200930193T SI 2310382 T1 SI2310382 T1 SI 2310382T1
Authority
SI
Slovenia
Prior art keywords
amidophenoxyindazoles
inhibitors
met
useful
amidophenoxyindazoles useful
Prior art date
Application number
SI200930193T
Other languages
English (en)
Slovenian (sl)
Inventor
Tiechao Li
Mark Andrew Pobanz
Chuan Shih
Zhipei Wu
Wei Jennifer Yang
Boyu Zhong
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SI2310382T1 publication Critical patent/SI2310382T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200930193T 2008-07-24 2009-07-15 Amidofenoksiindazoli uporabni kot inhibitorji c-met SI2310382T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8329408P 2008-07-24 2008-07-24
US8508208P 2008-07-31 2008-07-31
US10865908P 2008-10-27 2008-10-27
PCT/US2009/050640 WO2010011538A1 (en) 2008-07-24 2009-07-15 Amidophenoxyindazoles useful as inhibitors of c-met
EP09790440A EP2310382B1 (en) 2008-07-24 2009-07-15 Amidophenoxyindazoles useful as inhibitors of c-met

Publications (1)

Publication Number Publication Date
SI2310382T1 true SI2310382T1 (sl) 2012-04-30

Family

ID=41010247

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200930193T SI2310382T1 (sl) 2008-07-24 2009-07-15 Amidofenoksiindazoli uporabni kot inhibitorji c-met

Country Status (35)

Country Link
US (2) US8030302B2 (enExample)
EP (1) EP2310382B1 (enExample)
JP (1) JP5414794B2 (enExample)
KR (1) KR101334456B1 (enExample)
CN (1) CN102105462B (enExample)
AR (1) AR074632A1 (enExample)
AT (1) ATE546444T1 (enExample)
AU (1) AU2009274256B2 (enExample)
BR (1) BRPI0916286B8 (enExample)
CA (1) CA2731773C (enExample)
CL (1) CL2011000134A1 (enExample)
CO (1) CO6351737A2 (enExample)
CR (1) CR20110046A (enExample)
CY (1) CY1112595T1 (enExample)
DK (1) DK2310382T3 (enExample)
DO (1) DOP2011000009A (enExample)
EA (1) EA018385B1 (enExample)
EC (1) ECSP11010778A (enExample)
ES (1) ES2379587T3 (enExample)
HR (1) HRP20120202T1 (enExample)
IL (1) IL210490A (enExample)
JO (1) JO2788B1 (enExample)
MA (1) MA32594B1 (enExample)
MX (1) MX2011000925A (enExample)
MY (1) MY163852A (enExample)
NZ (1) NZ590013A (enExample)
PE (1) PE20110150A1 (enExample)
PL (1) PL2310382T3 (enExample)
PT (1) PT2310382E (enExample)
RS (1) RS52261B (enExample)
SI (1) SI2310382T1 (enExample)
SV (1) SV2011003816A (enExample)
TW (1) TWI365185B (enExample)
WO (1) WO2010011538A1 (enExample)
ZA (1) ZA201100219B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009303602B2 (en) 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
EP2408300B1 (en) 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
MX352844B (es) 2011-02-28 2017-12-11 Calitor Sciences Llc Compuestos de quinolina sustituidos y metodos de uso.
JP5970003B2 (ja) * 2011-03-04 2016-08-17 ローカス ファーマシューティカルズ インコーポレイテッド アミノピラジン化合物
KR20130118612A (ko) * 2012-04-20 2013-10-30 (주)네오믹스 신규한 아미노피리딘 유도체 및 이의 용도
CA2869316C (en) * 2012-05-09 2016-12-20 Eli Lilly And Company Anti-c-met antibodies
JP6433922B2 (ja) * 2013-02-27 2018-12-05 アレイ バイオファーマ、インコーポレイテッド インダゾール誘導体の調製に使用するための中間体およびその調製方法
CN104140393B (zh) * 2013-12-10 2016-09-21 郑州泰基鸿诺医药股份有限公司 一种芳环/芳杂环叔丁醇酯类化合物的制备方法
WO2015164161A1 (en) 2014-04-22 2015-10-29 Calitor Sciences, Llc Bicylcic pyrazolone compounds and methods of use
TW201716085A (zh) * 2015-08-12 2017-05-16 應克隆公司 癌症之組合療法
EP3442573A1 (en) * 2016-04-15 2019-02-20 Eli Lilly and Company Combination of ramucirumab and merestinib for use in treatment of colorectal cancer
JP7599819B2 (ja) 2016-06-02 2024-12-16 イムノコア リミテッド gp100特異的TCR-抗CD3 scFv融合タンパク質の投薬レジメン
EP3490676A1 (en) * 2016-07-29 2019-06-05 Eli Lilly and Company Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer
CN108069938A (zh) * 2016-11-15 2018-05-25 中国药科大学 2,4-二取代吡啶类化合物及其制备方法和应用
JP2019536771A (ja) * 2016-11-16 2019-12-19 イーライ リリー アンド カンパニー エクソン14スキッピング変異またはエクソン14スキッピング表現型を有する癌の治療
US20210283249A1 (en) 2016-11-16 2021-09-16 Eli Lilly And Company Combination therapy for cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype
CN107382968A (zh) * 2017-07-06 2017-11-24 北京万全德众医药生物技术有限公司 一种吲哚类c‑Met抑制剂的制备方法
CN107311983A (zh) * 2017-07-06 2017-11-03 北京万全德众医药生物技术有限公司 吲哚类小分子c‑met抑制剂
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
EP3480201A1 (en) 2017-11-06 2019-05-08 Oncostellae, S.L. New analogs as androgen receptor and glucocorticoid receptor modulators
CN111372925B (zh) 2017-11-24 2022-09-02 南京明德新药研发有限公司 作为c-MET/AXL抑制剂的尿嘧啶类化合物
CN110041316B (zh) * 2018-01-17 2022-04-19 药捷安康(南京)科技股份有限公司 Tam家族激酶/和csf1r激酶抑制剂及其用途
EP3762392B1 (en) 2018-03-08 2024-05-15 Wellmarker Bio Co., Ltd. Thienopyridine derivatives and pharmaceutical composition comprising same
PT3842425T (pt) * 2018-08-24 2024-07-02 Transthera Sciences Nanjing Inc Novo inibidor derivado de quinolina
CN112739691B (zh) * 2018-09-03 2023-05-23 泰励生物科技(上海)有限公司 用作抗癌药的trk抑制剂
JP2022554042A (ja) 2019-09-06 2022-12-28 ウェルマーカー・バイオ・カンパニー・リミテッド バイオマーカー型治療用組成物
US20240293386A1 (en) * 2021-06-22 2024-09-05 Lg Chem, Ltd. Novel compound as protein kinase inhibitor
WO2023110936A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Reversible macrocyclic kinase inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO155316C (no) * 1982-04-23 1987-03-11 Sintef Fremgangsmaate for fremstilling av magnetiske polymerpartikler.
US5484681A (en) * 1994-10-31 1996-01-16 Xerox Corporation Conductive composite particles and processes for the preparation thereof
IL114149A0 (en) * 1995-06-14 1995-10-31 Yeda Res & Dev Modified avidin and streptavidin molecules and use thereof
US5747577A (en) * 1995-12-27 1998-05-05 Xerox Corporation Conductive particles containing carbon black and processes for the preparation thereof
DE10046029A1 (de) 2000-09-18 2002-03-28 Bayer Ag Indazole
EP1400808B1 (en) * 2001-05-18 2006-06-28 Srl, Inc. Immunoassay method
US6956084B2 (en) * 2001-10-04 2005-10-18 Bridgestone Corporation Nano-particle preparation and applications
JP2004067703A (ja) * 2002-04-24 2004-03-04 Japan Science & Technology Corp 架橋ポリマー、微粒子および製造方法
US7192780B2 (en) * 2002-10-23 2007-03-20 Evident Technologies Fluorescent lifetime biological detection and imaging using water-stable semiconductor nanocrystals
ES2273047T3 (es) 2002-10-28 2007-05-01 Bayer Healthcare Ag Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa.
CN102746529B (zh) * 2003-07-17 2015-11-18 生命科技公司 包覆的磁性颗粒的制备方法
US7163998B2 (en) * 2003-09-09 2007-01-16 Eastman Kodak Company Stabilized polymer beads and method of preparation
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
RS55630B1 (sr) 2005-12-21 2017-06-30 Janssen Pharmaceutica Nv Triazolopiridazini kao modulatori tirozin kinaze
US7723330B2 (en) * 2006-03-07 2010-05-25 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
EP2038320B1 (en) * 2006-06-29 2014-03-12 Life Technologies AS Particles containing multi- block polymers
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
BRPI0717320A2 (pt) 2006-10-23 2013-10-22 Sgx Pharmaceuticals Inc Triazóis bicíclicos como moduladores de proteína cinase
WO2009003084A1 (en) 2007-06-27 2008-12-31 Arkema Inc. Process for the manufacture of hydrofluoroolefins

Also Published As

Publication number Publication date
CN102105462B (zh) 2014-07-23
US20100022529A1 (en) 2010-01-28
IL210490A0 (en) 2011-03-31
IL210490A (en) 2013-06-27
JP2011529054A (ja) 2011-12-01
HRP20120202T1 (hr) 2012-03-31
CY1112595T1 (el) 2016-02-10
DK2310382T3 (da) 2012-03-26
PT2310382E (pt) 2012-04-11
NZ590013A (en) 2012-06-29
RS52261B (sr) 2012-10-31
ATE546444T1 (de) 2012-03-15
AU2009274256B2 (en) 2013-07-11
EA018385B1 (ru) 2013-07-30
SV2011003816A (es) 2011-03-17
CL2011000134A1 (es) 2011-07-08
KR20110022691A (ko) 2011-03-07
WO2010011538A1 (en) 2010-01-28
JP5414794B2 (ja) 2014-02-12
ZA201100219B (en) 2012-06-27
CO6351737A2 (es) 2011-12-20
HK1155172A1 (en) 2012-05-11
US8030302B2 (en) 2011-10-04
USRE43878E1 (en) 2012-12-25
CA2731773C (en) 2013-03-12
CR20110046A (es) 2011-04-27
AU2009274256A1 (en) 2010-01-28
MY163852A (en) 2017-10-31
MX2011000925A (es) 2011-03-21
KR101334456B1 (ko) 2013-11-29
PL2310382T3 (pl) 2012-07-31
ECSP11010778A (es) 2011-02-28
DOP2011000009A (es) 2011-03-31
PE20110150A1 (es) 2011-03-07
TWI365185B (en) 2012-06-01
BRPI0916286B8 (pt) 2021-05-25
CN102105462A (zh) 2011-06-22
EP2310382B1 (en) 2012-02-22
AR074632A1 (es) 2011-02-02
TW201006817A (en) 2010-02-16
ES2379587T3 (es) 2012-04-27
EA201170252A1 (ru) 2011-06-30
MA32594B1 (fr) 2011-09-01
BRPI0916286B1 (pt) 2019-10-08
CA2731773A1 (en) 2010-01-28
JO2788B1 (en) 2014-03-15
EP2310382A1 (en) 2011-04-20

Similar Documents

Publication Publication Date Title
TWI365185B (en) Amidophenoxyindazoles useful as inhibitors of c-met
IL208136A0 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
IL211693A0 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
ZA201104749B (en) Benzonaphtyridine compounds used as inhibitors of autotaxin
IL212444A0 (en) Pyrazolylaminopyridines as inhibitors of fak
ZA201008808B (en) Novel phenylpyrazinones as kinase inhibitors
GB2459968B (en) Efficiency-based determination of operational characteristics
IL207100A0 (en) 2-amino-quinoline derivatives useful as inhibitors of b-secretase (bace)
IL218915B (en) Heterocyclic compounds used as pdk1 inhibitors
EP2249650A4 (en) ANILINOPYRIDINE AS A FAK HEMMER
ZA201100898B (en) Novel inhibitors
IL210573A0 (en) Compounds as kinase inhibitors
IL212119A0 (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
PL2297115T3 (pl) Pochodne di-alkoksychinazolin jako inhibitory receptora KDR
PL2133419T3 (pl) Zastosowania beta-dipeptydów cyjanoficyny
GB0621607D0 (en) Inhibitors of c-Met
IL206812A0 (en) Inhibitors of iap
IL208916A0 (en) Inhibitors of jnk
GB0821710D0 (en) Derivatives of dihydroindolone
PL386302A1 (pl) Nowa pochodna izotiazolopirydyny
GB0816125D0 (en) Novel inhibitors
GB0621980D0 (en) Inhibitors of c-Met
HU0800656D0 (en) Effective use of tea-composition